Depósito Digital de Documentos de la UAB Encontrados 16 registros  1 - 10siguiente  ir al registro: La búsqueda tardó 0.01 segundos. 
1.
8 p, 256.7 KB Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening / Román, R. (Institut Municipal d'Investigació Mèdica (Barcelona)) ; Sala, M. (Institut Municipal d'Investigació Mèdica (Barcelona)) ; Salas, D. (Centre Superior d'Investigació en Salut Pública, València) ; Ascunce, N. (Instituto de Salud Pública de Navarra) ; Zubizarreta, R. (Conselleria de Sanidade de la Xunta de Galicia) ; Castells, Xavier (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Background: Reducing the false-positive risk in breast cancer screening is important. We examined how the screening-protocol and women's characteristics affect the cumulative false-positive risk. Methods: This is a retrospective cohort study of 1 565 364 women aged 45-69 years who underwent 4 739 498 screening mammograms from 1990 to 2006. [...]
2011 - 10.1093/annonc/mdr032
Annals of oncology, Vol. 23 (march 2011) , p. 104-111  
2.
8 p, 500.4 KB Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer / Siena, S (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; Sartore-Bianchi, A (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ; Garcia-Carbonero, R (Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO, CIBERONC, Universidad Complutense, Madrid, Spain) ; Karthaus, M (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ; Smith, D (Department of Gastroenterology, University Hospital of Bordeaux, Hopital Haut Levaeque, Bordeaux, France) ; Tabernero, J (Universitat Autònoma de Barcelona) ; Van Cutsem, E (KU Leuven, Leuven, Belgium) ; Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ; Boedigheimer, M (Amgen Inc., Thousand Oaks, CA, USA) ; Ang, A (Amgen Inc., Thousand Oaks, CA, USA) ; Twomey, B (Amgen Inc., Thousand Oaks, CA, USA) ; Bach, B A (Amgen Inc., Thousand Oaks, CA, USA) ; Jung, A S (Amgen Inc., Thousand Oaks, CA, USA) ; Bardelli, A (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126  
3.
7 p, 740.6 KB Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) / Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ; Felip Font, Enriqueta (Universitat Autònoma de Barcelona) ; Matito, J (Institut d'Oncologia de la Vall d'Hebron) ; Mereu, Elisabetta (Universitat Pompeu Fabra) ; Navarro, A (Vall d'Hebron Institut d'Oncologia) ; Cedrés, S (Vall d'Hebron Institut d'Oncologia) ; Pardo Aranda, Núria (Universitat Autònoma de Barcelona) ; Martinez de Castro, A (Vall d'Hebron Institut d'Oncologia) ; Remon, J (Vall d'Hebron Institut d'Oncologia) ; Miquel, J M (Vall d'Hebron Institut d'Oncologia) ; Guillaumet-Adkins, A (Universitat Pompeu Fabra) ; Nadal, E (Institut Català d'Oncologia) ; Rodriguez Esteban, Gustavo (Universitat Pompeu Fabra) ; Arqués, O (Stem Cells and Cancer Group) ; Fasani, R (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Heyn, Holger (Universitat Pompeu Fabra) ; Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ; Palmer, H G (Stem Cells and Cancer Group) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. [...]
2017 - 10.1093/annonc/mdx396
Annals of oncology, Vol. 28 (july 2017) , p. 2451-2457  
4.
7 p, 176.2 KB Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review / García-Foncillas, J (Hospital Universitario Fundación Jiménez Díaz) ; Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Aranda, E (Hospital Reina Sofía, Cordoba) ; Díaz Rubio, E (Universidad Complutense de Madrid. Hospital Clínico San Carlos) ; López López, R (Hospital Clínico Universitario (Santiago de Compostela)) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia)
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. [...]
2017 - 10.1093/annonc/mdx501
Annals of oncology, Vol. 28 (september 2017) , p. 2943-2949  
5.
9 p, 341.6 KB Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, V. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wetterskog, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Sharabiani (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ; Grande, E. (Hospital Ramon y Cajal. Departamento de Oncologia Médica) ; Fernandez Perez, M. P. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Jayaram, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Castellano, D. (Hospital Universitario 12 de Octubre. Departamento de Oncologia Médica) ; Romanel, A. (Università di Trento. Centro di Biologia Integrata) ; Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Casadio, V. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gurioli, G. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Font, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Vazquez Estevez, S. (, Hospital Universitario Lucus Augusti. Departamento de Oncologia Médica) ; González del Alba, A. (Hospital Universitario Son Espases Mallorca. Departament d'Oncologia Médica) ; Mellado, B. (IDIBAPS Hospital Clinic. Departament d'Oncologia Médica) ; Fernandez Calvo, O. (Hospital de Ourense. Departamento de Oncologia Médica) ; Méndez Vidal, M. J. (Hospital Universitario Reina Sofía. Departamento de Oncologia Médica) ; Climent, M. A. (Instituto Valenciano de Oncología) ; Duran, I. (Instituto de Biomedicina de Sevilla) ; Gallardo, E. (Institut d'Investigació i Innovació Parc Taulí) ; Rodriguez, A. (Hospital de León. Departamento de Oncologia Médica) ; Santander, C. (Hospital Universitario Miguel Servet. Departamento de Oncologia Médica) ; Sáez, M. I. (Hospital Regional y Hospital Virgen de la Victoria, Malaga. Departamento de Oncologia Médica) ; Puente, J. (Hospital Clínico San Carlos. Departamento de Oncologia Médica) ; Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Wingate, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Dearnaley, D. (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ; Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ; De Giorgi, U. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ; Gonzalez Billalabeitia, E. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ; Attard, G. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ; Spanish Oncology Genitourinary Group ; Universitat Autònoma de Barcelona
2632A>G (p. T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3. 26; 95% CI 1. 47-not reached; P¼0. [...]
2017
Annals of Oncology, Núm. 28 (2017) , p. 1508-1516  
6.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, A. (Experimental Therapeutics Group) ; Bonache, S. (Oncogenetics Group) ; Morancho, B. (Vall d'Hebron Institut d'Oncologia) ; Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratú, G. (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital de la Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ; Baselga Torres, Josep, 1959-, (Memorial Sloan Kettering Cancer Center (USA)) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Díez, Orland (Hospital Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
7.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, J (Hospital Universitari Vall d'Hebron) ; Hozak, R R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, T (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A L (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R (Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic) ; Bodoky, G (Oncology, Szent László Hospital, Budapest, Hungary) ; Garcia-Carbonero, R (CIBERONC, Universidad Complutense, Madrid, Spain) ; Ciuleanu, T -E (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D C (Oncology, West Clinic, Memphis, USA) ; Prausová, J (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ; Siegel, R W (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R J (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, S A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, D (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  
8.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C S (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A X (Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA) ; Garon, E B (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J R (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L (Hospital Universitario Doce de Octubre. Departamento de Oncologia Médica) ; Baron, A D (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H H (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, D (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, I (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942  
9.
7 p, 242.6 KB Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies / Boeckx, N. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Koukakis, R. (Biostatistics, Amgen Ltd) ; Op de Beeck, K. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Rolfo, C. (Department of Oncology, Antwerp University Hospital, Edegem) ; Van Camp, G. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Douillard, J.-Y. (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ; André, T. (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ; Peeters, M. (Department of Oncology, Antwerp University Hospital, Edegem)
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868  
10.
8 p, 357.7 KB Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer / Grasselli, J (Institut Català d'Oncologia) ; Élez Fernández, María Elena (Universitat Autònoma de Barcelona) ; Caratù, G (Vall d'Hebron Institut d'Oncologia) ; Matito, J (Vall d'Hebron Institut d'Oncologia) ; Santos, C (Institut Català d'Oncologia) ; Macarulla Mercadé, Teresa (Universitat Autònoma de Barcelona. Hospital Universitari de la Vall d'Hebron) ; Vidal, J (Hospital del Mar. Departament d'Oncologia) ; Garcia, M (Institut Català d'Oncologia) ; Viéitez, J M (Hospital Universitario de Asturias. Departamento de Oncologia Médica) ; Paéz, D (Institut d'Investigació Biomèdica Sant Pau) ; Falcó, E (Hospital Universitari Son Llatzer. Departament d'Oncologia Mèdica) ; Lopez Lopez, C (Hospital Universitario Marqués de Valdecilla. Departamento de Oncología Médica) ; Aranda, E (Hospital Universitario Reina Sofía (Córdoba). Departamento de Oncología Médica) ; Jones, F (Sysmex Inostics, Mundelein, USA) ; Sikri, V (Sysmex Inostics, Mundelein, USA) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Fasani, R (Vall d'Hebron Institut d'Oncologia) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Montagut, C (Hospital del Mar. Departament d'Oncologia) ; Azuara, D (Institut Català d'Oncologia) ; Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ; Salazar, R (Institut Català d'Oncologia) ; Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301  

Depósito Digital de Documentos de la UAB : Encontrados 16 registros   1 - 10siguiente  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.